Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study
Gil Yosipovitch, Peter Foley, Caitriona Ryan, Jennifer C Cather, Kim A Meeuwis, Russel Burge, Alison Potts Bleakman, Chen-Yen Lin, William Malatestinic, Alice Gottlieb
JOURNAL OF SEXUAL MEDICINE | ELSEVIER SCI LTD | Published : 2018
INTRODUCTION: Genital psoriasis (GenPs) is common and distressing for patients, but is often not discussed with physicians, and no previous clinical trials have assessed the effects of biologics specifically on GenPs and its associated symptoms. AIM: To report results for novel patient-reported outcomes (PROs) for the assessment of symptoms and the sexual impact of GenPs before and after treatment in the IXORA-Q study. METHODS: IXORA-Q (NCT02718898) was a phase III, randomized, double-blind, placebo-controlled study of ixekizumab (80 mg/2 weeks after 160-mg initial dose) vs placebo for GenPs. Men and women ≥18 years old with moderate-to-severe GenPs and body surface area (BSA) ≥1% were asses..View full abstract
This study was funded by Eli Lilly and Company.